Longeveron Announces Phase 2 Clinical Trial in Japan to : co

New trial is in collaboration with Japan’s National Center for Geriatrics and Gerontology (NCGG) and Juntendo University Hospital...

Related Keywords

Miami , Florida , United States , Koto , Japan General , Japan , Tokyo , Japanese , Hidenori Arai , Brendan Payne , National Center , Drug Administration , Nasdaq , Longeveron Inc , Juntendo University Hospital , Devices Agency , Japan Pharmaceuticals , Juntendo Koto Geriatric Medical Center , Geoff Green , Chief Executive Officer , Hypoplastic Left Heart Syndrome , Japanese Phase , Medical Devices Agency , University Hospital , Koto City , Juntendo Koto Geriatric Medical , Aging Frailty , Metabolic Syndrome , Acute Respiratory Distress Syndrome , Nasdaq Lgvn , Longeveron ,